

(51) International Patent Classification:
A61K 31/4439 (2006.01)(21) International Application Number:
PCT/US2014/029661(22) International Filing Date:
14 March 2014 (14.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/792,812 15 March 2013 (15.03.2013) US(71) Applicant: DECIPHERA PHARMACEUTICALS, LLC
[US/US]; 643 Massachusetts, Suite 200, Lawrence, Kansas
66044 (US).

(72) Inventors; and

(71) Applicants : **AHN, YuMi** [US/US]; 4157 Blackjack Oak
Drive, Lawrence, Kansas 66047 (US). **VOGETI, Laksh-**
minarayana [US/US]; 170 Summer Street, Apt. # 5, Ar-
lington, Massachusetts 02474 (US). **CALDWELL,**
Timothy Malcolm [US/US]; 10489 Greenway Drive, Fish-
ers, Indiana 46037 (US).(72) Inventors: **KAUFMAN, Michael D.**; 4708 Muirfield
Drive, Lawrence, Kansas 66047 (US). **FLYNN, Daniel L.**;
4165 Blackjack Oak Drive, Lawrence, Kansas 66047 (US).(74) Agents: **FARMER, J. Dean** et al.; Cooley LLP, 1299
Pennsylvania Avenue, N.W., Suite 700, Washington, Dis-
trict of Columbia 20004-2400 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE
ACTIVITIES**Formula I**(57) Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and meta-
bolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the
treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.